A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone
Phase of Trial: Phase III
Latest Information Update: 18 Jan 2017
At a glance
- Drugs Cediranib (Primary) ; Lomustine
- Indications Glioblastoma
- Focus Registrational; Therapeutic Use
- Acronyms REGAL
- Sponsors AstraZeneca
- 22 Nov 2016 This trial has been completed in France.
- 07 Nov 2016 Status changed from active, no longer recruiting to completed.
- 23 Sep 2016 This trial was completed in Germany, according to European Clinical Trials Database.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History